"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Pedtrace (zinc, copper, manganese and chromium intravenous solution) ®-4 is a sterile, nonpyrogenic solution of four trace elements for use as an additive for total parenteral nutrition (TPN) in pediatric patients.
Each mL contains:
|Zinc Sulfate heptahydrate (equivalent to Zinc 0.5 mg)||2.2 mg|
|Cupric Sulfate pentahydrate (equivalent to Copper 0.1 mg)||0.39 mg|
|Manganese Sulfate monohydrate (equivalent to Manganese 25 mcg)||77 mcg|
|Chromic Chloride hexahyd rate (equivalent to Chromium 0.85 mcg)||4.36 mcg|
|Water for Injection||q. s.|
Zinc sulfate is chemically designated ZnSO4, a white crystalline compound freely soluble in water. Cupric sulfate is chemically designated CuSO4, a blue crystalline compound very soluble in water. Manganese sulfate is chemically designated MnSO4, a pale red, slightly efflorescent compound soluble in water. Chromic chloride is chemically designated CrCl3, a greenish compound soluble in water.
Sulfuric acid for pH adjustment (approximately 2.5).
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Pedtrace Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.